BridgeMD
ISIS 721744-CS3: An Open-Label Extension Study of ISIS 721744 in Patients with Hereditary Angioedema
EU CTIS ID: 2024-517249-15-00
What this study is testing
To evaluate the safety of extended dosing, and alternative dosing and/or dose frequency with ISIS 721744 in patients with HAE
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Satisfactory completion of ISIS 721744-CS2 (index study) through Week 17 with an acceptable safety and tolerability profile, per Sponsor and Investigator judgement
- 2. Able and willing to participate in a 64-week study
- 3. Females must be non-pregnant, non-lactating and either surgically sterile or post-menopausal
- 4. Males must be surgically sterile or abstinent or if engaged in sexual relations with a female of child-bearing potential, participant is utilizing an acceptable contraceptive method.
- 5. Participants must have access to, and the ability to use, ≥ 1 acute medication(s) (e.g., plasma-derived or recombinant C1- inhibitor (C1INH) concentrate or a bradykinin-2 [BK-2] antagonist) to treat angioedema attacks
You likely can't join if
- 1. Have any new condition or worsening of an existing condition or change or anticipated change in medication or other reason, which in the opinion of the Investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in or completing the study
The study team makes the final eligibility decision.
Where it's taking place
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.